Teleflex study links catheter technology to 70% lower CLABSI risk
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq advance as soft inflation tempers Fed rate-hike bets
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
September 29, 2026 6:30 AM EDTPeer-reviewed publication in the American Journal of Infection Control demonstrates the use of CVCs protected with Arrowg+ard Technology are associated with a statistically significant and clinically meaningful reduction in the hazard of CLABSI compared with plain CVCs1.
WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream... More
